Even as Sun Pharmaceutical Industries assimilates Takeda-owned URL's generic business (scripintelligence.com, 18 December 2012), there is speculation that the Indian firm may also be keen to build up its branded generics business in China, possibly via an alliance or even a partial acquisition.
An executive with an investment advisory firm, who did not want to be identified, told Scrip that there was some general chatter about Sun's growing interest in its Asian neighbor and that